

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of claims:

1. (Currently Amended) A dry powder inhalation composition ~~comprising,~~ consisting of (a) at least 0.25% ~~[[()]]~~by weight of the composition~~[[()]]~~ of an active ingredient with a mean particle size of less than 10 microns in diameter, and (b) a pharmaceutically acceptable particulate carrier with a mean particle size of less than 250 microns in diameter.

2. (Currently Amended) The dry powder inhalation composition according to ~~Claim~~ claim 1, wherein the composition comprises less than 10% ~~[[()]]~~by weight of the composition~~[[()]]~~ of the active ingredient.

3. (Currently Amended) The dry powder inhalation composition according to ~~Claim~~ claim 1 or ~~Claim~~ claim 2, wherein the composition comprises from about 0.26 to about 1% ~~[[()]]~~by weight of the composition~~[[()]]~~ of the active ingredient.

4. (Currently Amended) The dry powder inhalation composition according to ~~Claim~~ claim 1, which comprises from about 0.265 to about 0.5% ~~[[()]]~~by weight of the composition~~[[()]]~~ of the active ingredient.

5. (Currently Amended) The dry powder inhalation composition according to ~~Claims~~ claim 1 or 4, wherein the carrier is lactose.

6. (Currently Amended) The dry powder inhalation composition according to ~~Claims~~ claim 1 or 4, wherein the active

ingredient is formoterol or a pharmaceutically acceptable derivative thereof.

7. (Canceled).

8. (Currently Amended) A capsule containing from 1 to 25 mg of a dry powder inhalation composition according to ~~Claims~~ claim 1 or 4.

9. (Currently Amended) A ~~MDPI~~ multidose dry powder inhaler comprising a reservoir containing the dry powder inhalation composition of ~~Claim~~ claim 1 or 4.

10. (Currently Amended) A method for the treatment of chronic obstructive pulmonary disease by the step of administering the dry powder inhalation composition of ~~Claim~~ claim 1 or 4.

11. (New) A dry powder inhalation composition consisting of (a) at least 0.25% by weight of the composition of an active ingredient with a mean particle size of less than 10 microns in diameter, and (b) a pharmaceutically acceptable particulate carrier with a mean particle size from about 89 to about 110 in diameter.

12. (New) A dry powder inhalation composition consisting of (a) at least 0.25% by weight of the composition of an active ingredient with a mean particle size of less than 10 microns in diameter, and (b) a pharmaceutically acceptable particulate carrier with a mean particle size from about 50 to about 60 microns in diameter.

13. (New) A dry powder inhalation composition consisting of (a) at least 0.25% by weight of the composition of an active ingredient with a mean particle size of less than 10 microns in

diameter, and (b) a pharmaceutically acceptable particulate carrier with a mean particle size from about 60 to about 90 microns in diameter.

14. (New) The dry powder inhalation composition according to claim 9, wherein said multidose dry powder inhaler is capable of producing a 6 mcg dose having a fine particle fraction of about 48%.

15. (New) The dry powder inhalation composition according to claim 9, wherein said multidose dry powder inhaler is capable of producing a 12 mcg dose having a fine particle fraction of about 49%-54%.